Johanna Rubin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Johanna Rubin has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adeodata Kekitiinwa
Baylor College of Medicine Children's Foundation Kampala Uganda
1 shared publication - Anders Tegnell
Public Health Agency of Sweden, Stockholm, Sweden
1 shared publication Anton Pohanka
Department of Laboratory Medicine, Division of Clinical Pharmacology Karolinska Institutet Stockholm Sweden
1 shared publication- Bernice Aronsson
Licensing Division, Swedish Medical Products Agency, Uppsala, Sweden
1 shared publication - Björn Zethelius
Use and Information Division, Swedish Medical Products Agency, Uppsala, Sweden
1 shared publication - Celestino Obua
Mbarara University of Science and Technology, Mbarara, Uganda
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e12937
Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden. Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented. Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups. National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80. Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.
- 16 October 2025
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e12937
Open AccessOverview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden. Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented. Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups. National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80. Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.
- Open Access
- 8 October 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 464-478
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study
Aims: Interindividual variations in efavirenz (EFV) plasma concentrations are extensive, but paediatric data on its consequences for viral control are scarce. The aim of this study was to explore the role of genetic variation in achieving therapeutic efavirenz plasma concentrations in a cohort of Ugandan children and the linkage between genetic CYP2B6 variants, EFV plasma variability, viral resistance and viral outcome.Methods: Ninety‐nine treatment‐naïve children, aged 3–12 years and living with HIV, were followed for 24 weeks after ART initiation assessing mid‐dose efavirenz plasma concentrations, HIV RNA, HIV drug resistance and adherence. Polymorphisms in genes coding for drug‐metabolizing enzymes were genotyped. Efavirenz concentrations were determined by liquid chromatography coupled with high‐resolution tandem mass spectrometry. Metabolizer phenotype was predicted from composite genotypes of CYP2B6 (c.516G>T and c.983 T>C). A mixed effects restricted maximum likelihood regression model was used to identify important factors for efavirenz exposure.Results: Efavirenz plasma concentrations were below the therapeutic interval (1000–4000 mg/mL) in 12–17% and above in 21–24% of measurements. Eight children had persisting subtherapeutic concentrations, five of which failed virologically and three acquired at least one new resistant mutation. Multivariate modelling explained 70% of interindividual variation in plasma concentration, with treatment duration, adherence, CYP2B6c.136A>G, and metabolizer phenotype as independent predictors of EFV concentration. In univariate analysis, metabolizer phenotype explained 50% of interindividual variation.Conclusions: Metabolizer phenotype explained 50% of interindividual variation in efavirenz plasma concentration. Autoinduction was not confirmed and >33% of the concentrations were outside the therapeutic interval. Subtherapeutic concentrations worsened virological resistance and outcomes. Genotype‐based dosing may help avert both sub‐ and supratherapeutic efavirenz plasma concentrations in Ugandan children.
- 8 October 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 464-478
Open AccessSub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study
Aims: Interindividual variations in efavirenz (EFV) plasma concentrations are extensive, but paediatric data on its consequences for viral control are scarce. The aim of this study was to explore the role of genetic variation in achieving therapeutic efavirenz plasma concentrations in a cohort of Ugandan children and the linkage between genetic CYP2B6 variants, EFV plasma variability, viral resistance and viral outcome.Methods: Ninety‐nine treatment‐naïve children, aged 3–12 years and living with HIV, were followed for 24 weeks after ART initiation assessing mid‐dose efavirenz plasma concentrations, HIV RNA, HIV drug resistance and adherence. Polymorphisms in genes coding for drug‐metabolizing enzymes were genotyped. Efavirenz concentrations were determined by liquid chromatography coupled with high‐resolution tandem mass spectrometry. Metabolizer phenotype was predicted from composite genotypes of CYP2B6 (c.516G>T and c.983 T>C). A mixed effects restricted maximum likelihood regression model was used to identify important factors for efavirenz exposure.Results: Efavirenz plasma concentrations were below the therapeutic interval (1000–4000 mg/mL) in 12–17% and above in 21–24% of measurements. Eight children had persisting subtherapeutic concentrations, five of which failed virologically and three acquired at least one new resistant mutation. Multivariate modelling explained 70% of interindividual variation in plasma concentration, with treatment duration, adherence, CYP2B6c.136A>G, and metabolizer phenotype as independent predictors of EFV concentration. In univariate analysis, metabolizer phenotype explained 50% of interindividual variation.Conclusions: Metabolizer phenotype explained 50% of interindividual variation in efavirenz plasma concentration. Autoinduction was not confirmed and >33% of the concentrations were outside the therapeutic interval. Subtherapeutic concentrations worsened virological resistance and outcomes. Genotype‐based dosing may help avert both sub‐ and supratherapeutic efavirenz plasma concentrations in Ugandan children.
- 30 June 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (9) , 1838-1839
Communication is key to sustainable vaccination programs
- 30 June 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (9) , 1838-1839
Communication is key to sustainable vaccination programs